A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

Exclusion Criteria

• •1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
• •2. Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
• •3. Subject has guttate, pustular, erythrodermic, or other non-plaque forms of psoriasis.
• •4. Subject has used any of the following topical preparations or procedures in the
• •Treatment Area:
• •* Emollients/moisturizers within four days prior to Visit I;
• •* Topical anti-psoriatic drugs on the body (excluding the scalp) within 14 days of Visit 1; or
• •* Phototherapy ( including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days of Visit 1.
• •5. Subject has used any of the following systemic medications or procedures:
• •* Systemic tofacitinib, ampremilast, methotrexate, retinoids, corticosteroids, and cyclosporine or analogous products with in three months of Visit I; or
• •* Systemic anti-inflammatory biologic therapy (i.e., FDA-approved or experimental therapy) with in five half-lives of the biologic prior to Visit 1.
• •6. Subject is currently using lithium or Plaquenil.
• •7. Subject is currently using a beta-blocking medication (e.g., propranolol) or angiotensin converting enzyme (ACE) inhibitor at a dose that has not been stabilized, in the opinion of the investigator.
• •8. Subject, in the opinion of the investigator, has had prolonged exposure to natural or artificial sources of ultraviolet (UV) radiation within 30 days prior to Visit 1 or intends to have such exposure during the study that is likely to modify the subject's disease.
• •9. Subject is currently enrolled in an investigational drug or device study.
• •10. Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.
• •11. Subject has a history of sensitivity to any of the ingredients in the test article.
• •12. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the investigator.